Our vision is a U.S. Military Force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide.

## Medical Countermeasure Systems (MCS)

Command Overview Briefing

**Presented at:** 

Other Transaction Authority Industry Day

### **COL Russell E. Coleman**

Joint Project Manager Medical Countermeasure Systems russell.e.coleman.mil@mail.mil

June 15, 2015





DISTRIBUTION STATEMENT A: APPROVED FOR PUBLIC RELEASE. DISTRIBUTION IS UNLIMITED.

## **Bottom Line Up Front**



- MCS wants to gather information regarding the use of Other Transaction Authority (OTA) consortium approach
  - What *incentives can we offer* to entice Non-Traditional Defense Contractors to work with the DoD in an OTA consortium approach?
  - What *issues must be solved* to develop a successful OTA consortium approach?
  - Is there *another approach* that will *provide a better solution*?

## How can we work with you? Ask questions?

## **WHO WE ARE**






## Medical Countermeasure Systems (MCS)



VISION A U.S. military force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide

### MISSION To provide U.S. military forces and the nation safe, effective, and innovative medical solutions to counter CBRN threats



20150615 MCS Industry Day

# **Spectrum of Medical Countermeasures (MCM)**





## PREVENTION


**PROPHYLAXIS SUSTAINS THE FORCE** 

**DIAGNOSTIC IDENTIFIES THREATS TO TREAT** 

THERAPEUTIC SAVES LIVES

TREATMENT

20150615 MCS Industry Day



## WHAT WE DO





## **Products in the Pipeline**



LEGEND:	PREVENTION DIAGNOSTICS THERAPEUTICS DoD		FDA	★= FDA Cl	eared				
		MDD	MSA	MS		MSC			
CAPABILITY	PRODUCT Recombinant Botulinum A/B Vaccine		IND	PHASE1	PHASE 2	PHASE 3	BLA	NEXT MS MS C 2017	FDALICENSURE
	Plague Vaccine							MS C 2015	2019
	Bioscavenger							MS C 2019	2019
PREVENTION	V								
	Filovirus Vaccine							MS B 2017	2025
	Ricin Vaccine							MS B TBD	TBD
	WEVEE Vaccine							MS B 2019	2029
	PRODUCT	MDD	MS A DEV	MS PRE-CLINICAL	ANALYTICAL	MSC CLINICAL	( <i>LRIP</i> ) 510K	NEXT MS	FDA CLEARED
	Next Generation Diagnostic System – Increment 1							MS C 2017	2017
DIAGNOSTIC	Next Generation Diagnostic System – Increment 2							MS B 2015	TBD
	JBAIDS Pre-EUA Kits: Typhus, Burkholdieria/Melioidosis							Pre-EUA	2014
	JBAIDS Food & Water Pathogens							2014	N/A
	PRODUCT	MDD	MSA IND	MS PHASE1	B PHASE2	MSC PHASE3	( <i>LRIP</i> )	NEXT MS	FDA APPROVAL
	Advanced Anticonvulsant System						INDA	FRP 2017	2017
	Emerging Infectious Disease (EID) Therapeutics – Flu							MS C 2016	2016
THERAPEUTIC	CS Hemorrhagic Fever Virus (HFV) Therapeutic							MS B 2015	2021
	EID Therapeutics – New Indication							MS C 2021	2022
	Improved Nerve Agent Treatment System							MS B 2017	2021

As of Date: 01/09/15 MDD=Material Decision Document
20150615 MCS Industry Day

ocument MS=Milestone

LRIP=Low Rate Initial Production

FRP=Full Rate Production

EUA=Emergency Use Authorization

## **Products Fielded**



LEGEND: PREVENTION DIAGNOSTICS THERAPEUTICS										
				NUMBE	R OF PROL	DUCTS DELIVERED				
CAPABILITY	PRODUCT	FDA LICENSURE	FY02-12	FY13	FY14	TOTAL				
	Anthrax Vaccine Adsorbed	2002	13.2 M	.66 M	.52 M	14.4 M				
PREVENTION	Smallpox Vaccine	2007	4.5 M	.32 M	.21 M	5.0 M				
	Vaccinia Immune Globulin	2005	288	240	0	528				
CAPABILITY	PRODUCT	FDA Clearance	FY02-12	FY13	FY14	TOTAL				
DIACNOSTICS	Joint Biological Agent Identification & Diagnostic System (JBAIDS)	2005	340	0	0	340				
DIAGNOSTICS	JBAIDS Assay Kits	2005-11	22.8 K	2.29 K	1.30 K	26.4 K				
		FDA	D/02.48							
CAPABILITY	PRODUCT	FDA APPROVAL	FY02-12	FY13	FY14	TOTAL				
THERAPEUTICS	Antidote Treatment Nerve Agent Autoinjector (ATNAA)	2002	9.7 M	.28 M	0	9.9 M				
	Convulsant Antidote Nerve Agents (CANA)	1990	5.2 M	.13 M	.02 M	5.3 M				
	Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP)	2003	.49 M	.03 M	.01 M	.53 M				

As of Date: 01/09/15

## **HOW WE DO IT**





## **DoD: Meeting the Needs** of the Warfighter






## **SAFE & EFFECTIVE FDA APPROVED PRODUCTS**

20150615 MCS Industry Day

## **Integration of the DoD and FDA Product Development Models**






20150615 MCS Industry Day

## **Product Development and the Animal Rule**

### TRADITIONAL LICENSURE PATHWAY



### ANIMAL RULE LICENSURE PATHWAY

	PRE-CLINICAL	PHASE I	PHASE 2		PHASE 3			MARKETING &
DISCOVERY	Y ANIMAL MODEL SELECTION		ANIMAL MODEL REFINEMENT		VOTAL ANIMAL EFFICACY	FDA APPROVAL	POST MARKETING COMMITMENTS	
	ID OF CORRE	LATE		DEVELOP/QUALIFY CORRELATE ASSAYS		VALIDATION OF CORRELATE ASSAYS		

Animal Rule development requires integrated clinical and non-clinical programs

• Allows for approval of products for which efficacy testing in humans is unethical

### Extensive Animal Model and Assay Development

- Efficacy is demonstrated in more than one, well defined animal model
- Well controlled animal studies provide data that are likely to predict a benefit in humans
- Greater emphasis and reliance placed upon validated assays for demonstration of efficacy

Animal Rule Citation: 21 CFR Parts 314 and 601; New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible


## WHAT ARE WE DOING TO IMPROVE





## Enhancing Stakeholder Partnerships





## Enhancing Industry Partnerships



- We are developing products that we hope will never be used and for which the threat is totally unpredictable (don't know what, where, when or how much)
- Poor ROI makes it difficult to attract "right" partners, even when we pay all R&D costs
- We are trying to better understand the incentives/disincentives that affect industry decisions on working with us:
  - MCM OTA Consortium
  - Working with Tuft's Center for the Study of Drug Development to bring together an expert panel to make recommendations on incentivizing industry (e.g., FDA priority voucher-like incentives)



- What *incentives can we offer* to entice Non-Traditional Defense Contractors to work with the DoD in an OTA consortium approach?
- What *issues must be solved* to develop a successful OTA consortium approach?
- Is there another approach that will provide a better solution?

## How can we work with you? Ask questions?



### Russell E. Coleman, Ph.D. Colonel, U.S. Army Joint Project Manager

Medical Countermeasure Systems (MCS) Joint Project Management Office Office: 301.619.7400 | Blackberry: 240.575.8599 Email: russell.e.coleman.mil@mail.mil

### Edward T. Clayson, Ph.D. Deputy Joint Project Manager

Medical Countermeasure Systems (MCS) Joint Project Management Office Office: 301.619.7624 | Blackberry: 301.693.9570 Email: <u>edward.t.clayson.civ@mail.mil</u>

### Medical Countermeasure Systems (MCS) Project Management Offices

301-619-2156

MCS-Fort Detrick (HQ) 1564 Freedman Drive Fort Detrick, MD 21702-5041 301-619-7400

#### MCS-Frederick Annex 110 Thomas Johnson Drive, Ste 240 Frederick, MD 21702-5041

**MCS-Fort Belvoir** 

10109 Gridley Road, Bldg 314, 2nd Floor Fort Belvoir, VA 22060-5865 703-704-2374

GNOS

DIAGNOSTICS

Our vision is a U.S. Military Force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide.

## Medical Countermeasure Systems (MCS)-Diagnostics (Dx)

Diagnostics Portfolio Briefing

VD BIOLOG

**Presented at:** 

Other Transaction Authority Industry Day

### Jason Opdyke, Ph.D.

Senior Scientist, Diagnostics Tauri Group Support Medical Countermeasure Systems jason.opdyke.ctr@mail.mil

June 15, 2015

DISTRIBUTION STATEMENT A: APPROVED FOR PUBLIC RELEASE. DISTRIBUTION IS UNLIMITED.



### **Mission**

Develop, acquire, integrate, and field identification technologies and FDA-cleared diagnostic devices intended for Service Members to aid in the early diagnosis, prevention, and treatment of the effects of exposure to chemical, biological, and radiological (CBR) agents.





## • Current products and programs

- Joint Biological Agent Identification and Diagnostic System (JBAIDS)
   lifecycle management: Fielded
- Joint Handheld Biological Identifier (JHBI)
- Next Generation Diagnostics System (NGDS) Increment 1: MS C FY16
- NGDS Increment 2: Preparation for milestone (MS) B FY16

Fielded/Development Products

### Joint Biological Agent Identification and Diagnostic System (JBAIDS)

Ruggedized mobile laboratory analytical system that provides rapid and highly accurate identification of multiple biological agents in clinical, food, and environmental samples

Anthrax Assay

 Environmental Surveillance Assays

- Plague AssayTularemia Assay
- H5N1 Avian Flu Assay
- Q-Fever Assay
- Influenza A&B Typing Assay
- Influenza A Subtype Assay



	Next Generation Diagnostics System (NGD	OS) Increment 1
Description	Common medical test equipment and diagnostic platform for multiple biological threat agents, automated and integrated across all levels of the military health system	
Last Milestone	MS A, Feb 2012	
Clinical / FDA Accomplishment	<ul> <li>Authorized Emergency Use Authorization (EUA) for NGDS Bio Threat-Ebola panel</li> </ul>	
Next Steps FDA	<ul> <li>→Next Acquisition MS: MS C, FY16</li> <li>→Next Clinical MS: 510(k)</li> <li>→Projected FDA Clearance Date: FY16</li> </ul>	

*Development Products / Business Opportunities* 



	Next Generation Diagnostics System (NGDS) Increment 2											
Description	Common medical test equipment & diagnostic platform. Expand breadth of Inc 1 diagnostics capability to difficult pathogens, toxins, traditional Chemical Warfare Agents, non-traditional agents and radiation exposures											
Last Milestone	Material Development Decision (MDD)											
Clinical / FDA Accomplishment	• N/A											
Next Steps FDA	<ul> <li>→Next Acquisition MS: MS B FY16</li> <li>→Next Clinical MS: N/A</li> <li>→Projected FDA Clearance Date: TBD</li> </ul>											

Milestone = MS

### • Business Opportunities

- Request for proposal (RFP) anticipated 1QFY16 for a diagnostic platform
  - Desired features of such systems include high sensitivity and specificity,
  - Ease of use (Clinical Laboratory Improvement Amendments (CLIA) waiver),
  - Multiplexing capability,
  - Integrated sample preparation, and low logistics burden,
  - A single system that could integrate multiple detection technologies is preferred

Advanced Development Products



	Joint Hand-held Biological Identifier In	crement 1
Description	Provide the capability to rapidly and accurately identify bio-agents at the point of contact from environmental samples with a handheld device	
Last Milestone	MS B, Mar 2015	
Clinical / FDA Accomplishment	• NA	
Next Steps FDA	→Next Acquisition MS: MS C, FY16 →Next Clinical MS: N/A; environmental identifier →Projected FDA Clearance Date: NA	

### • Business Opportunities

 – RFP anticipated in 4QFY15/1QFY16 to support polymerase chain reaction assay manufacture for peace-time and surge capabilities.

Milestone = MS



- MCS-Dx wants to gather information regarding the use of Other Transaction Authority (OTA) consortium approach
  - What *incentives* can we offer to entice Non-Traditional Defense diagnostics developers to work with the DoD in an OTA consortium approach?
  - What *issues must be solved* to develop a successful OTA consortium approach?
  - Is there *another approach* that will *provide a better solution*?

### How can we work with you? Ask questions?

## **Contact Us**



### Jennifer Dabisch Acting, Joint Product Manager

Diagnostics (Dx) Medical Countermeasure Systems (MCS) Office: 301.619.4434 | Blackberry: 301.693.1382 Email: jennifer.c.dabisch.civ@mail.mil

### Jason Opdyke , Ph.D. Senior Scientist

Diagnostics (Dx) Contractor Support, Tauri Group Medical Countermeasure Systems (MCS) Office: 301.619.2881 | Blackberry: 240.409.7747 Email: jason.opdyke.ctr@mail.mil

### Medical Countermeasure Systems (MCS) Project Management Offices

#### MCS-Fort Detrick (HQ) 1564 Freedman Drive Fort Detrick, MD 21702-5041 301-619-7400

### MCS-Frederick Annex

110 Thomas Johnson Drive, Ste 240 Frederick, MD 21702-5041 301-619-2156

#### **MCS-Fort Belvoir**

10109 Gridley Road, Bldg 314, 2nd Floor Fort Belvoir, VA 22060-5865 703-704-2374 Our vision is a U.S. Military Force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide.

## Medical Countermeasure Systems (MCS)-Joint Vaccine Acquisition Program (JVAP)

Vaccines Portfolio Briefing

**Presented at:** 

Other Transaction Authority Industry Day

VD BIOLOG

### **LTC Victor Suarez**

Joint Product Manager Joint Vaccine Acquisition Program (JVAP) victor.a.suarez.mil@mail.mil

June 15, 2015

JOINT VACCINE ACQUISITION PROGRAM

DISTRIBUTION STATEMENT A: APPROVED FOR PUBLIC RELEASE. DISTRIBUTION IS UNLIMITED.



- JVAP Mission and Vision
- Integrating DoD and FDA product development models
- Products Fielded and in the Pipeline
- Program Overviews
- Biological Prophylaxis Technology Needs

## **MCS-Joint Vaccine Acquisition Program (MCS-JVAP)**



### Mission

Develop, produce & field FDA-licensed vaccine systems to protect the Warfighter from biological agents



### Vision

Be the Joint Warfighter's and the Nation's first choice for advanced development of vaccine products which protect our military and partners from biological agents

## **Products Fielded and in the Pipeline**



LEGEND:PREVENTIONDoDFDA $\star$  = FDA Cleared

CAPABILITY	PRODUCT	FDA LICENSURE	FY02-12	FY13	FY14	TOTAL
PREVENTION	Anthrax Vaccine Adsorbed	2002	13.2 M	.66 M	.39 M	14.3 M
	Smallpox Vaccine	2007	4.5 M	.32 M	.17 M	5.0 M
	Vaccinia Immune Globulin	2005	288	240	0*	528

	MDD	MS A	MS	S B	MS C ( <i>LRIP</i> )			
CAPABILITY	PRODUCT	IND	PHASE 1	PHASE 2	PHASE 3	BLA	NEXT MS	FDA LICENSURE
	Recombinant Botulinum A/B Vaccine	Jun 2004	Jan 2009	Nov 2011	2020	2021	MS C 2018	2022
	Plague Vaccine	Oct 2004	Jun 2007	Nov 2012	2019	2019	MS C 2020	2020
PREVENTION	Filovirus Vaccine	2016	2017	2020	2023	2024	MS B 2017	2025
	Ricin Vaccine	Jan 2014	2016	TBD	TBD	TBD	MS B TBD	TBD
	WEVEE Vaccine	2017	2019	2024	2027	2028	MS B 2019	2029

As of Date: 06/08/15

\*Note: JVAP fielded 240 treatment doses of VIGIV in early FY15 (4 Oct 15)

20150615 MCS Industry Day

## Botulinum A/B Vaccine (rBV A/B)




#### ACAT II / E&MD Phase

### **Program Description**



- Botulinum Vaccine will be a Food and Drug Administration-licensed product to protect against aerosolized exposure to botulinum neurotoxins serotypes A and B
- Contractors: DynPort Vaccine
   Company, Frederick, MD; Battelle,
   W. Jefferson, OH; Jublilant, Hollister
   Stier, Spokane, WA; FUJIFILM
   Diosynth Biotechnologies (FDBU),
   Morrisville, NC
- Contract Type: Cost Plus Award Fee
- IOC/FOC: 150K / 500K TEDs\* Draft CPD



#### **Recent Milestones or Events**

- AUG 14 Revised APB approved by MDA
- NOV 14 Pivotal animal study report complete
- JAN 15 CWMD WG Tripwire-endorsed APB
- Feb 15 Antigen B Feasibility runs completed at new CMO
- Mar 15 FCB Tripwire brief-endorsed APB to JCB

#### **Near Term Milestones or Events**

- 3QFY15 Antigen A Technology Transfer FMEA
- 3QFY15 Antigen B DOE initiated
- 4QFY15 Antigen A development runs

#### **Threat Overview**

- One of the most lethal nerve toxins known (50-100 times more toxic than sodium cyanide)
- Estimated 1 gram of crystalline toxin, evenly dispersed and inhaled, has potential to kill 1.5M people
- Treatment without vaccination requires enormous demands on intensive medical care
- Historical use as BWA includes: Russia and Iraq stockpiled BOT Toxin up to 20,000 liters, enough to kill earth's entire population
- Japanese Cult Aum Shinrikyo attempted to use Botulinum Toxin on several occasions between 1990-1995 in Japan

#### Vaccine Manager: MAJ John Nuckols

## **Plague Vaccine**




### ACAT II / E&MD Phase

### **Program Description**



- Plague Vaccine will prevent pneumonic plague from aerosolized exposure to the bacteria *Yersinia pestis.*
- **Contractors:** DynPort Vaccine Company, Frederick MD; Jublilant, Hollister Stier, Spokane, WA; FUJIFILM Diosynth Biotechnologies (FDBU), Morrisville, NC
- Contract Type: Cost Plus Award Fee
- IOC/FOC: 150K / 410K TEDs\* Draft CPD

\*TED=Troop Equivalent Dose



### **Recent Milestones or Events**

- Nov 14 Completion of studies to demonstrate that human antibodies to plague provide full protection against aerosol infection
- Feb 15 FDA acceptance of Cynomolgus macaques as primary animal model for pivotal efficacy studies
- Mar 15 FDA concurred with parallel pivotal animal study w/ Phase 3 trial, non-clinical approach to determine efficacy in humans and efficacy statistical approach

### **Near Term Milestones or Events**

- 1QFY16 End of Phase 2 meeting with FDA
- 1QFY16 CMC drug substance submission to FDA

### **Threat Overview**

- Threat due to historical evidence of its use as a BWA (Japan WWII, Russia developed offensive plague capabilities). Natural outbreaks still occur world-wide (Madagascar Dec 2013 = 70 deaths)
- As BWA, once infected, Soldiers are capable of spreading disease through coughing and bodily fluids. If left untreated for 24 hrs, aerosolized infections are invariably fatal.
- Vaccine prophylaxis is considered best protection since wearing PPE at time of covert attack is impractical
- Gentamicin used as an antibiotic, but must be started within first 24 hrs to avoid high mortality rates

Vaccine Manager: Dr. David Heath

#### 20150615 MCS Industry Day

## **Filovirus Vaccine**



### Potential ACAT II / TD Phase

### **Program Description**



- MCS-JVAP will develop a trivalent vaccine system to protect against Ebola Sudan, Ebola Zaire and Marburg viruses. Program is developing competitive prototypes (VLP, VSV).
- **Contractors:** Battelle, Columbus, OH; TBRI, San Antonio, TX; Profectus Bioservices, Baltimore MD; USAMRIID
- Contract Type: CPFF / FPI / FFP
- IOC/FOC: 96 K / 350K TEDs\* Draft CDD for Filo Vaccine Increment


\*TED=Troop Equivalent Dose

### **Recent Milestones or Events**

- Oct 14- awarded VLP contract to Fraunhofer for manufacturing efforts
- Feb 15- Fielded 50,000 GUP doses of VSV $\Delta$ G to support Phase 2/3 trials in West Africa
- Mar 15- Fielded VSV∆G PEP vials to Walter Reed National Military Medical Center for High Risk Exposures
- 2QFY15 Initiation of non-clinical duration studies

#### **Near Term Milestones or Events**

- 3QFY15- cGMP manufacturing of trivalent VSV N4CT1 candidate
- 4QFY15- Initiate first trivalent Phase 1 clinical trial (VSV N4CT1)



#### **Threat Overview**

- Presents a current threat beyond anything we've seen prior
- Former active Russian program to weaponize Marburg virus
- In 1992, Aum Shinrikyo attempted to obtain Ebola virus to make a bio-weapon from an outbreak in Zaire (DRC).
- Can be suitable for bio-weapon use because:
  - can be disseminated via aerosols
  - have a low infectious dose
  - cause high morbidity and mortality
  - cause fear and panic
  - now more readily available

#### Vaccine Manager: Ms. Rebecca Kurnat

## **Ricin Vaccine**



### Potential ACAT II / TD Phase

#### **Recent Milestones or Events Program Description** JUL 13 – Funding removed in POM 15 MCS-JVAP is developing a new vaccine for the DoD intended to NOV 13 – Briefed DJPEO - continue to Phase 1b with government protect against aerosolized exposure candidate (RV*Ec*<sup>™</sup>) to ricin toxin • MAR 14 – FDA acceptance of submitting intradermal clinical Government Labs: USAMRIID; WRAIR protocol for Phase 1b Contractors: University of Nebraska; JAN 15 – GMP vaccine manufactured for Phase 1b/c Battelle, Columbus, OH FEB 15 – Ricin challenge stock well characterized, stable and large • Contract Type: FFP Tasks animal aerosol delivery system qualified • IOC/FOC: 290K/2.1M TEDs\* Draft **Near Term Milestones or Events** CDD for Ricin Vaccine (Dec 12) 3QFY15 – Initiate Bulk Drug Substance technology transfer to the ADM 3QFY15 – Phase 1b Clinical Trial initiation \*TED=Troop Equivalent Dose 3QFY15 – Complete NHP (AG) LD50 and Natural History studies **Threat Overview Ricin Vaccine Schedule** Used in assassination attempts world-wide Fiscal Year PRIOR 18 20 14 15 16 17 Ease of production and can distribute via mail Milestones & TD E&MD Phases Russia studied its use as a bioweapon MŠ A MS B Irag was suspected to have experimented with "crude" unpurified Capabilities Documents Draft CDD CDD ricin toxin • Toxic by all routes of exposure, highly toxic via aerosol; resulting in Manufacturing epitheilial necrosis w/in hrs of exposure, hemorrhagic edema and Technology Transfer to the ADM Activities GMP (Ph1 death w/in 24-72 hrs Phase 1B CT Phase 1A CT No effective therapy is available Testing Animal Mode <u>Development</u> Vaccine Manager: Mr. Chris Dorsey

#### 20150615 MCS Industry Day

#### UNCLASSIFIED

#### 34

## Western, Eastern & Venezuelan Equine Encephalitis (WEVEE) Vaccine




Potential ACAT II / TD Phase

### **Program Description**



- MCS-JVAP is developing a trivalent vaccine for DoD to protect against aerosolized exposure to three strains of alphaviruses; western, eastern and Venezuelan equine encephalitis viruses. Program is developing competitive prototypes.
- Contractors: NIAID, Bethesda, MD; Battelle, Colombus, OH
- Contract Type: IAA/ FFP /CPIF
- IOC/FOC: 290K / 2.0M TEDs\* Draft CDD for WEVEE Vaccine (Feb 13)

\*TED=Troop Equivalent Dose



#### **Recent Milestones or Events**

- JAN 14 Selected virus strains for NHP model
- JAN 14 Completed in-life portion of VLP NHP challenge study
- MAR 14 Completed cGMP BDS runs for VLP candidate
- MAR 15 Pre-IND submitted or VLP/Initiate VRP work from Filo at CSU
- APR 15 Purchased VRP Intellectual Property

#### **Near Term Milestones or Events**

- 3QFY15 Submit strain selection to FDA
- 3QFY15- Award contracts for animal model efforts
- 3QFY15 Initiate manufacturing process development of VRP vaccine candidate

#### **Threat Overview**

- The level of incapacitation, mortality, simplification of production and amenability of genetic manipulation have established WEE, EEE, and VEE viruses as high threat BWA.
- Easy to produce at high titers and have low infectious doses, highly infectious using aerosols, can be easily lyophilized (freeze dried) and stored for decades
- Estimated cost for supportive care associated with disease is approx \$1M per patient
- Was weaponized in the past by both Russia and US

Vaccine Manager: Mr. Andrew Glenn

## **Biological Prophylaxis Technology Needs** (1 of 2)



## • Capability Gaps

- Rapid onset to protection (novel adjuvants)
- Desire longer duration of protection
- Stability of products at higher storage temperatures
- Alternate routes of administration

## Product Development Tools

- Animal model development
- Natural history studies
- Strain characterization and selection
- Adjuvant development to support enhanced immunogenicity

## • In the S&T Pipeline for Transition Near Term (2016-21)

- Tularemia vaccine
- Multi-Botulinum toxin vaccine (additional serotypes)

# **Biological Prophylaxis Technology Needs** (2 of 2)

### • S&T Push Efforts

- New Generation Anthrax Vaccine
- Q-Fever Vaccine
- Melioidosis Glanders Vaccine
- SEB Vaccine

### • Far-Term Modernization Goals (FY21+)

- Initiate development of prophylaxes to address the full range of biological hazards
- Develop monoclonal antibodies to provide prophylaxis against weaponized infectious agents and toxins



- MCS-JVAP wants to gather information regarding the use of Other Transaction Authority (OTA) consortium approach
  - What *incentives can we offer* to entice Non-Traditional Defense *vaccine developers* to work with the DoD in an OTA consortium approach?
  - What *issues must be solved* to develop a successful OTA consortium approach?
  - Is there *another approach* that will *provide a better solution*?

### How can we work with you? Ask questions?

# **Contact Us**



### Victor A. Suarez Lieutenant Colonel, U.S. Army Joint Product Manager

Joint Vaccine Acquisition Program (JVAP) Medical Countermeasure Systems (MCS) Office: 301.619.7083 | Blackberry: 301.693.1618 Email: <u>victor.a.suarez.mil@mail.mil</u>

### Nicole R. Kilgore, MS, PMP Deputy, Joint Product Manager

Joint Vaccine Acquisition Program (JVAP) Medical Countermeasure Systems (MCS) Office: 301.619.8441 | Blackberry: 301.660.0475 Email: <u>nicole.r.kilgore.civ@mail.mil</u>

#### Medical Countermeasure Systems (MCS) Project Management Offices

MCS-Fort Detrick (HQ) 1564 Freedman Drive Fort Detrick, MD 21702-5041 301-619-7400

#### MCS-Frederick Annex

110 Thomas Johnson Drive, Ste 240 Frederick, MD 21702-5041 301-619-2156

#### **MCS-Fort Belvoir**

10109 Gridley Road, Bldg 314, 2nd Floor Fort Belvoir, VA 22060-5865 703-704-2374 Our vision is a U.S. Military Force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide.

# Medical Countermeasure Systems (MCS)-Chemical Defense Pharmaceuticals (CDP)

Autoinjector Portfolio Briefing

ND BIOLOG

**Presented at:** 

Other Transaction Authority Industry Day

### **Dr. David Smith**

Deputy Joint Product Manager Medical Countermeasure Systems Chemical Defense Pharmaceuticals david.j.smith222.civ@mail.mil

June 15, 2015

**CHEMICAL DEFENSE PHARMACEUTICALS** 

DISTRIBUTION STATEMENT A: APPROVED FOR PUBLIC RELEASE. DISTRIBUTION IS UNLIMITED.

### MCS-Chemical Defense Pharmaceuticals (MCS-CDP)

### <u>Mission</u>

Provide the Warfighter and the Nation robust & affordable FDA-approved lifesaving medical countermeasure drug capabilities against chemical, radiological and nuclear threats



# Product Overview

**Chemical Defense Medical Products** 





# **INATS Overview**



# • INATS is an enhanced treatment regimen against the effects of nerve agent poisoning


- Development of an adjunct centrally-acting therapeutic for addition to the family of systems to increase survival against NTAs
  - Lead candidate Scopolamine
- Development of broad spectrum oxime to replace the currently fielded oxime (2-PAM)
  - Lead candidate MMB4 DMS
- Conduct of studies to generate data to support the use of the PB pretreatment against agents other than soman



 NTA-relevant product to replace and achieve the improved product performance over the currently fielded Antidote Treatment – Nerve Agent Autoinjector (ATNAA)

### **INATS** *Current vs. Future*





20150615 MCS Industry Day

UNCLASSIFIED



- MCS-CDP wants to gather information regarding the use of Other Transaction Authority (OTA) consortium approach
  - What *incentives can we offer* to entice Non-Traditional Defense *developers* to work with the DoD in an OTA consortium approach?
  - What *issues must be solved* to develop a successful OTA consortium approach?
  - Is there *another approach* that will *provide a better solution*?

### How can we work with you? Ask questions?

# **Contact Us**



#### Marla J. Ferguson Lieutenant Colonel, U.S. Army Joint Product Manager

Chemical Defense Pharmaceuticals (CDP) Medical Countermeasure Systems (MCS) Office: 301.619.8425 | Blackberry: 240.529.3895 E-mail: <u>marla.j.ferguson.mil@mail.mil</u>

### David Smith, Ph.D. Deputy Joint Project Manager

Chemical Defense Pharmaceuticals (CDP) Medical Countermeasure Systems (MCS) Office: 301.619.8027 | Blackberry: 301.693.9392 E-mail: <u>david.j.smith222.civ@mail.mil</u>

#### Medical Countermeasure Systems (MCS) Project Management Offices

#### MCS-Fort Detrick (HQ)

1564 Freedman Drive Fort Detrick, MD 21702-5041 301-619-7400

#### MCS-Frederick Annex

110 Thomas Johnson Drive, Ste 240 Frederick, MD 21702-5041 301-619-2156

#### **MCS-Fort Belvoir**

10109 Gridley Road, Bldg 314, 2nd Floor Fort Belvoir, VA 22060-5865 703-704-2374 Our vision is a U.S. Military Force that has a full medical countermeasure capability to fight and win in any CBRN battlespace worldwide.

# Medical Countermeasure Systems (MCS)-Biological Defense Therapeutics (BDTX)

Therapeutics Portfolio Briefing

**Presented at:** 

BIOLOGICAL DEFENSE THERAPEUTICS

Other Transaction Authority Industry Day

### LTC Eric G. Midboe

Joint Product Manager BioDefense Therapeutics (BDTX) eric.g.midboe.mil@mail.mil

June 15, 2015


DISTRIBUTION STATEMENT A: APPROVED FOR PUBLIC RELEASE. DISTRIBUTION IS UNLIMITED.

ND BIOLOGN



- Organizational Overview
- Biological Defense Therapeutics Mission
- Biological Defense Therapeutic Product Lines

## BDTX Organizational Structure



UNCLASSIFIED

### MCS-Biological Defense Therapeutics(MCS-BDTx)

### <u>Mission</u>

Provide U.S. military forces and the nation safe, effective, innovative, and affordable therapeutic solutions to counter traditional, emerging and engineered biological threats

### **Vision**

A healthy and creative environment which inspires a talented team of professionals to rapidly develop innovative therapeutic solutions for dynamic biological threats.



# BDTX Importance of Therapeutics



- Therapeutics play a critical /strategic role in biological defense
  - Shield and sustain (prophylactic and treatment) against known viral, bacterial, and toxin BWAs including engineered or multi-drug resistant strains/variants
- The BDTX portfolio of therapeutics will enable Force Readiness and Sustainment
  - Broad spectrum anti-viral therapeutics will counter many threats with one drug
  - Broad spectrum anti-bacterial therapeutics will protect the warfighter from BWA that have been engineered for multi-drug resistance (MDR)
  - Platform based therapeutics will be targeted to respond to emerging or engineered strains/variants and may be approved with an EUA

### Rapid treatment returns the force to duty

### **BDTX Medical Countermeasure** Development

Development		NOT THE ALL ATERME AND AND
FDA Approval Process Drug Discovery	5,000 - 10,000 Compounds	Likelihood of FDA Approval*
Pre Clinical	250 Compounds	
Phase I Clinical Trials	5 Compounds	19.0%

**Engineering & Manufacturing** Phase 2 Clinical Trials **Development Phase** 

Phase 3 Clinical Trials

**FDA Review** 

**Production Decision Production &** 

DoD

Acquisition

**Process** 

Material Solution **Analysis Phase** 

**Technology Maturation & Risk Reduction Phase** 

**Deployment Phase** 

**Large Scale Production** 

Compound

\*Source: BioMedTracker (February 2013) Clinical Development Success Rates Jan 1-2003-Dec 31-2012. Uses of Secondary Data to Drive Primary Strategy

24.4%

60.2%

88.2%

- Pipeline needs to be expanded to meet the requirements of the warfighter (BWA)
- S&T pipeline must continually be replenished with new compounds

#### UNCLASSIFIED

### **Emerging Infectious Disease** (EID) Tx Overview



### Goal:

To deliver a U.S. Food and Drug Administration (FDA)-approved, broadspectrum medical countermeasure (MCM) to the Warfighter for protection against naturally occurring or biologically engineered viruses

**Users:** The Services, the nation, and allied forces



### Future:

- FDA approval: FY16
- Favipiravir will be further developed to address other RNA viruses of concern to the DOD

### Status:

- Contract awarded to MediVector, Inc. (Boston, MA) on 14 March 2012 to develop Favipiravir, a broad-spectrum MCM:
  - Efficacious against multiple strains of influenza, including the 2009 H1N1 virus, H7N9 virus and drug-resistant influenza strains;
  - Addresses a pronounced gap in the existing interagency viral MCM development portfolio
- Milestone B: 1Q FY13
- Phase 1 and Phase 2 clinical trials are complete
- End of Phase 2 (EOP2) meeting held in September 2013
- Phase 3 clinical trials: Initiated Dec 2013

### Hemorrhagic Fever Virus (HFV) MCM Overview



### Goal:

Deliver FDA approved therapeutics targeting hemorrhagic fever viruses.

-Current efforts are focused on RNA-directed platform technologies against Ebolavirus

**Users:** The Services, the nation, and allied forces



*Currently, there are no available vaccines or therapeutics to prevent or treat Ebola infections* 

### Status:

- Ebola MCM (FDA "fast track") Will Complete Phase 1 human clinical trials 1Q FY15
- 83% efficacious when administered within 2 days after exposure in non-human primates

### **Future:**

- Milestone B: 4Q FY15
- Pilot animal efficacy studies: FY15
- Pivotal animal efficacy studies: FY16-17
- FDA approval: FY21 (Ebola MCM)
- Develop new drug candidates for other HFV indications

### Countermeasures for Multi-Drug Resistance-Bacterial (CMDR-B) Overview



### Goal:

Develop Medical Countermeasures (MCMs) for multi-drug resistant (MDR) bacteria, focusing on Biological Warfare Agents (BWAs) and organisms that are genetically modified to be MDR. The resulting product(s) will be US FDA-approved to prevent or minimize effects of MDR bacterial exposures

#### Users: The Services and allied forces



Future:

• Milestone A: 1QFY15

### Status:

- CMDR-B secured FY15-19 POM funding
- Market Survey and Request for Information completed
- Translational Teaming Charter with the Joint Science and Technology Office (JSTO) to support product development throughout entire RDT&E life cycle
- Exploring Translational Teaming opportunities outside the Chemical and Biological Defense Program (CBDP) including: US Army Medical Materiel Development Activity (USAMMDA); United States Army Medical Research Institute for Infectious Diseases (USAMRIID); Military Infectious Diseases Research Program (MIDRP); Critical Reagents Program (CRP); Advanced Development Manufacturing Capability (ADMC); Biomedical Advanced Research and Development Authority (BARDA)

### **Bio-Toxin Therapeutics Overview**



### Goal:

Develop post exposure prophylaxis (PEP) and treatment solutions to mitigate the detrimental effects caused by bio-toxins

### **Capability Status:**

Currently the program is in Concept Development stage (Pre-MDD). The program is working with JSTO CBD to update Bio-Toxin Capability Transition Agreement (CTA) and identify mature technology for advanced development

### Future:

- Pursue traditional product development and conduct a Materiel Development Decision (MDD) in FY15
- Seek a Milestone A Decision sometime in FY16



- MCS-BDTX wants to gather information regarding the use of Other Transaction Authority (OTA) consortium approach
  - What *incentives* can we offer to entice Non-Traditional Defense therapeutic developers to work with the DoD in an OTA consortium approach?
  - What *issues must be solved* to develop a successful OTA consortium approach?
  - Is there *another approach* that will *provide a better solution*?

### How can we work with you? Ask questions?

# **Contact Us**



#### Eric G. Midboe, Ph.D. Lieutenant Colonel, U.S. Army Joint Product Manager

Biological Defense Therapeutics (BDTX) Medical Countermeasure Systems (MCS) Office: 703.704.1178 | Blackberry: 703.407.5367 E-mail: <u>eric.g.midboe.mil@mail.mil</u>

### David A. Klaasse Deputy Joint Product Manager

Biological Defense Therapeutics (BDTX) Medical Countermeasure Systems (MCS) Office: 703.704.0638 | Blackberry: 703.405.9021 E-mail: <u>david.a.klaasse.civ@mail.mil</u>

### Medical Countermeasure Systems (MCS) Project Management Offices

#### MCS-Fort Detrick (HQ)

1564 Freedman Drive Fort Detrick, MD 21702-5041 301-619-7400

#### MCS-Frederick Annex

110 Thomas Johnson Drive, Ste 240 Frederick, MD 21702-5041 301-619-2156

#### **MCS-Fort Belvoir**

10109 Gridley Road, Bldg 314, 2nd Floor Fort Belvoir, VA 22060-5865 703-704-2374